Targets › SLC34A2
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Dec 2027.
Involved in actively transporting phosphate into cells via Na(+) cotransport. (UniProt, O95436)
Open in Phaseline: the race on SLC34A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gilead Sciences | TUB-040 NaPi2b antibody-drug conjugate (ADC) | SLC34A2 | Phase 1 | Ovarian Cancer | Dec 2027 |
| Mersana Therapeutics | upifitamab rilsodotin (XMT-1536) anti-NaPi2b antibody-drug conjugate | SLC34A2 | Phase 1 | Platinum Resistant Ovarian Cancer | – |
Ovarian Cancer (2) Platinum Resistant Ovarian Cancer (1)
small molecule (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.